8-K: Precision BioSciences Q3 2025 Results & Pipeline Update

Precision BioSciences reported Q3 2025 financial results and provided updates on its gene editing pipeline, including progress for PBGENE-HBV and PBGENE-DMD.

Summary

• Reported financial results for the third quarter ended September 30, 2025.
• Announced strong progress across its gene editing pipeline, including PBGENE-HBV and PBGENE-DMD.
• PBGENE-HBV Phase 1 ELIMINATE-B trial: new data to be presented at The Liver Meeting 2025; commenced dosing in Cohort 3.
• PBGENE-DMD: Investigational New Drug (IND) filing anticipated by end of 2025, Phase 1 initiation in the first half of 2026, with initial data expected in the second half of 2026.
• Expected cash runway into the second half of 2027, enabling achievement of clinical milestones for PBGENE-HBV and PBGENE-DMD.
• Net loss was $21.8 million, or ($1.84) per share (basic and diluted), for the quarter ended September 30, 2025.
• Cash, cash equivalents, and restricted cash were approximately $71.2 million as of September 30, 2025.

Sentiment

Score: 6

Explanation: While financial results show increased losses and decreased cash, the significant clinical progress in key pipeline programs (PBGENE-HBV, PBGENE-DMD) and positive data from partnered programs, coupled with an extended cash runway, provide a moderately positive outlook for future value creation despite current financial burn.

Positives

• PBGENE-HBV Phase 1 ELIMINATE-B trial showed the therapy to be well-tolerated by patients in Cohorts 1 and 2.
• PBGENE-HBV demonstrated a substantial HBsAg reduction in all patients across Cohort 1, with one patient achieving a durable HBsAg reduction of approximately 50% from baseline that was ongoing seven months following initial dose administration.
• The Data Monitoring Committee recommended proceeding with dosing Cohort 3 for PBGENE-HBV given the favorable safety profile of Cohorts 1 and 2.
• A U.S. Patent (No. 12,410,418) was issued for the PBGENE-HBV ARCUS nuclease, with an expiration date in March 2042.
• PBGENE-DMD preclinical data demonstrated durable improvements in muscle function over time through increased dystrophin expression and dystrophin-positive cells in a DMD mouse model.
• PBGENE-DMD showed significantly improved maximum force output over untreated DMD mice at three, six, and nine months post-treatment.
• Partnered program ECUR-506 (iECURE-OTC) demonstrated complete clinical response in the first participant at the lowest dose level (1.3x10^13 GC/kg).
• Partnered program Azer-Cel (Imugene) showed an overall response rate of 81% in relapsed/refractory diffuse large B-cell lymphoma patients, including seven complete responses and six partial responses.
• Azer-Cel also achieved an 83% overall response rate (50% complete responses) in CAR T-naive patients.
• Received an $8 million milestone payment in cash and stock from Imugene on October 31, 2025.
• Implemented operating efficiencies in July 2025, leading to reductions in early research and general & administrative expenses in Q3 2025.
• Expected cash runway into the second half of 2027, enabling achievement of clinical milestones for PBGENE-HBV and PBGENE-DMD.

Negatives

• Total revenues for the quarter ended September 30, 2025, were less than $0.1 million, a decrease from $0.6 million for the same period in 2024, primarily due to less billable effort under the Novartis Agreement.
• Net loss increased to $21.8 million in Q3 2025 from $16.4 million in Q3 2024.
• Net loss per share (basic and diluted) was ($1.84) in Q3 2025, compared to ($2.25) in Q3 2024, indicating a higher absolute loss per share despite the lower numerical value.
• Cash, cash equivalents, and restricted cash decreased to $71.2 million as of September 30, 2025, from $108.468 million as of December 31, 2024.
• Working capital decreased to $36.709 million as of September 30, 2025, from $80.009 million as of December 31, 2024.
• Total stockholders' equity decreased to $16.634 million as of September 30, 2025, from $56.393 million as of December 31, 2024.

Risks

• Ability to become profitable.
• Ability to procure sufficient funding to advance programs.
• Risks associated with capital requirements, anticipated cash runway, and requirements under current debt instruments, including the ability to raise additional capital.
• Operating expenses and the ability to predict them accurately.
• Limited operating history.
• The progression and success of programs and product candidates.
• Limited ability or inability to assess the safety and efficacy of product candidates.
• The risk that other genome-editing technologies may provide significant advantages over ARCUS technology.
• Dependence on ARCUS technology.
• The initiation, cost, timing, progress, achievement of milestones, and results of research and development activities and preclinical and clinical studies.
• Public perception about genome editing technology and its applications.
• Competition in the genome editing, biopharmaceutical, and biotechnology fields.
• Ability to identify, develop, and commercialize product candidates.
• Pending and potential product liability lawsuits and penalties.
• The U.S. and foreign regulatory landscape applicable to the development of product candidates.
• Ability to advance product candidates into, and successfully design, implement, and complete, clinical trials.
• Potential manufacturing problems associated with the development or commercialization of any product candidates.
• Delays or difficulties in enrolling patients.
• Changes in interim top-line and initial data that are announced or published.
• Product candidates not working as intended or causing undesirable side effects.
• Risks associated with applicable healthcare, data protection, privacy, and security regulations.
• Ability to obtain orphan drug designation or fast track designation for product candidates or to realize the expected benefits of these designations.
• Ability to obtain and maintain regulatory approval of product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate.
• The rate and degree of market acceptance of any product candidates.
• Ability to effectively manage the growth of operations.
• Ability to attract, retain, and motivate executives and personnel.
• Effects of system failures and security breaches.
• Insurance expenses and exposure to uninsured liabilities.
• Effects of tax rules.
• Effects of any pandemic, epidemic, or outbreak of an infectious disease.
• The success of existing collaboration and other license agreements, and the ability to enter into new collaboration arrangements.
• Current and future relationships with and reliance on third parties including suppliers and manufacturers.
• Ability to obtain and maintain intellectual property protection for technology and any product candidates.
• Potential litigation relating to infringement or misappropriation of intellectual property rights.
• Effects of natural and manmade disasters, public health emergencies, and other natural catastrophic events.
• Effects of sustained inflation, supply chain disruptions, and major central bank policy actions.
• Market and economic conditions.
• Risks related to ownership of common stock, including fluctuations in stock price.
• Ability to meet the requirements of and maintain listing of common stock on Nasdaq or other public stock exchanges.

Future Outlook

The company anticipates an IND filing for PBGENE-DMD by the end of 2025, with Phase 1 initiation in DMD patients expected in the first half of 2026 and initial data in the second half of 2026. Additional data readouts for the ELIMINATE-B trial are planned for early 2026. The company expects its existing cash and equivalents, potential near-term cash from CAR T transactions, operating efficiencies, operational receipts, and availability of its at-the-market (ATM) facility to extend its cash runway into the second half of 2027, enabling achievement of clinical milestones for PBGENE-HBV and PBGENE-DMD.

Management Comments

• "Throughout the third quarter, we made strong progress across our gene editing pipeline and reported compelling Phase 1 safety and efficacy data for PBGENE-HBV at the International Coalition to Eliminate HBV Cure Symposium. We're also eagerly awaiting a late-breaking oral presentation at AASLD on November 10th." Michael Amoroso, Chief Executive Officer.
• "The PBGENE-HBV data presented so far this year has shown proof of durable activity and a safety profile that allows us to continue dose escalation in pursuit of achieving a complete cure for hepatitis B patients." Michael Amoroso, Chief Executive Officer.
• "With great excitement, in 2026 we anticipate starting the first-in-human clinical trial with our second program, PBGENE-DMD for DMD patients, following our targeted IND submission by the end of 2025." Michael Amoroso, Chief Executive Officer.
• "We are highly encouraged by the unique preclinical data showing the potential to restore a nearly full length dystrophin gene which is native to the human body with the goal of improving function over time." Michael Amoroso, Chief Executive Officer.

Industry Context

Precision BioSciences operates in the highly competitive and rapidly evolving gene editing and biopharmaceutical industry. Its ARCUS platform aims to differentiate itself through its cutting mechanism, smaller size, and simpler structure, potentially enabling more defined therapeutic outcomes. The progress in PBGENE-HBV and PBGENE-DMD positions the company in the race for curative treatments for chronic infectious diseases and genetic disorders, competing with other gene therapy and gene editing companies. The successful advancement of partnered programs like iECURE-OTC and Azer-Cel also highlights the broader applicability and validation of the ARCUS platform in areas like metabolic disorders and oncology, where allogeneic CAR T therapies are a significant area of innovation.

Comparison to Industry Standards

• The durable HBsAg reduction of approximately 50% from baseline in a PBGENE-HBV Cohort 1 patient, ongoing seven months post-dose, is a promising early signal in the challenging field of chronic Hepatitis B cure, where sustained viral suppression and functional cure remain high unmet needs. This compares favorably to current standard-of-care antivirals which suppress but rarely cure.
• PBGENE-DMD's preclinical data showing increased dystrophin expression and significant functional muscle improvement in a DMD mouse model, with the goal of restoring a near-full length dystrophin protein, aims to differentiate from other gene therapy approaches (e.g., micro-dystrophin AAV therapies from Sarepta Therapeutics or Pfizer) that deliver truncated versions of the protein, potentially offering a more robust and durable functional benefit.
• The 81% overall response rate and 50% complete response rate in CAR T-naive patients for Azer-Cel (allogeneic CAR T) are competitive with or exceed some autologous CAR T therapies (e.g., Yescarta, Kymriah) in certain lymphoma subtypes, especially considering the advantages of an off-the-shelf allogeneic product in terms of accessibility and manufacturing.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancement, but current financial losses and cash burn could lead to short-term pressure. The extended cash runway provides stability.
• Patients (Hepatitis B): Continued progress in PBGENE-HBV offers hope for a potentially curative treatment, with promising early safety and efficacy signals.
• Patients (Duchenne Muscular Dystrophy): Anticipated IND filing and Phase 1 initiation for PBGENE-DMD offer a new therapeutic approach aiming for durable functional improvements.
• Employees: Operating efficiencies implemented in July 2025 included employment-related reductions, indicating potential impact on workforce.
• Partners (Imugene, iECURE): Continued collaboration and positive clinical data for partnered programs validate the ARCUS platform and generate milestone payments.

Next Steps

• Late-breaking oral presentation at The Liver Meeting 2025 (AASLD) on November 10, 2025, featuring new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV.
• Additional data readouts for the ELIMINATE-B trial planned in early 2026.
• Investigational New Drug (IND) filing for PBGENE-DMD anticipated by end of 2025.
• Phase 1 initiation in Duchenne Muscular Dystrophy (DMD) patients anticipated in the first half of 2026.
• Initial data for PBGENE-DMD expected in the second half of 2026.
• Data from the iECURE-OTC (OTC-HOPE) trial expected in the first half of 2026.
• Imugene has scheduled a Type C meeting with the U.S. FDA to discuss potential pivotal study design options for azer-cel.

Key Dates

Recommendation

While the financial results show increased losses and a decrease in cash, the company has made significant clinical and preclinical progress in its core gene editing programs (PBGENE-HBV and PBGENE-DMD), which are critical for long-term value. The extended cash runway into H2 2027 provides sufficient time to reach key clinical milestones. The positive data from partnered programs further validates the ARCUS platform. However, the substantial cash burn and the early stage of the pipeline warrant a cautious approach. Investors should hold to monitor the upcoming clinical data readouts and IND filing, which are crucial catalysts for future valuation.

Keywords

Gene editing, ARCUS, PBGENE-HBV, Hepatitis B, PBGENE-DMD, Duchenne Muscular Dystrophy, Clinical Trials, Biotechnology, Pharmaceutical, Financial Results, Q3 2025, Nasdaq, DTIL, SEC Filing, 8-K